Successful Control of Life‐Threatening Thrombocytosis with a Blood Processor

Greenberg, BR; Watson-Williams, E.

doi:10.1046/j.1537-2995.1975.15676082242.x

Cited by 25 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the meantime, therapeutic depletion of excess WBCs from CML patients was reported by Freireich and associates as a part of the NCI‐IBM cell separator development effort 15 . Although leukapheresis did not prove to be beneficial in this illness, the “proof of principle” provided by this experience set the stage for application of leukapheresis to patients with leukostasis in the context of acute leukemia and the use of therapeutic plateletpheresis 16 to address clinical manifestations of thrombocytosis.…”

Section: Clinical Application Of Tamentioning

confidence: 86%

Therapeutic apheresis: history, clinical application, and lingering uncertainties

McLeod

2010

Transfusion

View full text Add to dashboard Cite

Section: Clinical Application Of Tamentioning

confidence: 86%

Therapeutic apheresis: history, clinical application, and lingering uncertainties

McLeod

2010

Transfusion

View full text Add to dashboard Cite

“…Previous studies have shown that thombocyteapheresis can reduce the platelet count in a patient with thrombocytosis using intermittent ow centrifugation devices. 6,7 It is believed that patients with thrombotic or haemorrhagic manifestations associated with ET should be treated with thrombocyteapheresis in combination with cytoreductive therapy .…”

Section: Discussionmentioning

confidence: 99%

Thrombocyteapheresis for the Treatment of Essential Thrombocythemia Presented as a Digital Ischaemia- A Case Report

Hasan¹,

Haque²,

Mamun³

et al. 2019

Bangladesh Med J

View full text Add to dashboard Cite

Thrombotic manifestations of essential thrombocytosis (ET) may be a life threatening condition. The conventional cytoreductive therapy or radioisotopes may take long time to reduce the platelet counts whereas thrombocyteapheresis can reduce the count more rapidly. Here the reported case is an essential thrombocytosis presented with digital ischaemia and was managed with intermittent flow centrifugal thrombocyteapheresis combined with hydroxyurea to reduce the platelet count.Thrombocytopharesis is an effective method and safe to reduce platelet count acutely. Thrombocyteapheresis has been done for the first time for the treatment of essential thrombocythemia (ET) in BSMMU probably also in Bangladesh. Bangladesh Med J. 2017 May; 46 (2): 56-58

show abstract

“…Modern intermittent-flow and continuous-flow automated centrifugation systems are effective means of rapidly and effectively reducing platelet counts [63–65]. Currently used systems for platelet apheresis include COBE ® Spectra, Terumo ® Trima and Fenwal Amicus ® .…”

Section: Discussionmentioning

confidence: 99%

The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review

et al. 2017

View full text Add to dashboard Cite

Extreme thrombocytosis induces an acquired thrombotic-hemorrhagic diathesis, and left uncontrolled is a harbinger of potentially fatal vascular complications. Currently, cytoreduction with medical therapy remains the mainstay of hyperthrombocytosis management. However, it offers a less-than-ideal option in situations where a rapid reduction in platelets is urgently needed, as in the presence of vital end-organ ischemia or to ameliorate of life-threatening hemorrhage. The role of thrombocytapheresis, or plateletpheresis, in hyperthrombocytosis has become increasingly obsolete given the proactive titration of cytoreductive therapies and early identification and correction of reversible causes of reactive thrombocytosis. Despite its narrowed indications, plateletpheresis continues to offer a valuable temporizing measure in platelet count reduction before cytoreductive agents exert their maximal effect. In this context, it is important for the treating physician to be aware of the symptoms and risks associated with hyperthrombocytosis to inform best clinical practices. In this review, we discuss the role of plateletpheresis in the modern-day management of hyperthrombocytosis in patients with myeloproliferative neoplasms through a case based review of the literature. It becomes apparent throughout the discussion that the decision to perform plateletpheresis should be individualized based upon the clinical scenario, degree of thrombocytosis, available infrastructure and every patient’s risk profile.

show abstract

Successful Control of Life‐Threatening Thrombocytosis with a Blood Processor

Cited by 25 publications

References 2 publications

Therapeutic apheresis: history, clinical application, and lingering uncertainties

Therapeutic apheresis: history, clinical application, and lingering uncertainties

Thrombocyteapheresis for the Treatment of Essential Thrombocythemia Presented as a Digital Ischaemia- A Case Report

The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review

Contact Info

Product

Resources

About